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Myo-inositol (myo-Ins) has a physiological role in mammalian gametogenesis and embryonic development and a positive clinical
impact on human medically assisted reproduction. We have previously shown that mouse embryo exposure to myo-Ins through
preimplantation development in vitro increases proliferation activity and blastocyst production, representing an improvement in
culture conditions. We have herein investigated biochemical mechanisms elicited by myo-Ins in preimplantation embryos and
evaluated myo-Ins effects on postimplantation/postnatal development. To this end naturally fertilized embryos were cultured in
vitro to blastocyst in the presence or absence of myo-Ins and analyzed for activation of the PKB/Akt pathway, known to modulate
proliferation/survival cellular processes. In parallel, blastocyst-stage embryos were transferred into pseudopregnant females and
allowed to develop to term and until weaning. Results obtained provide evidence that myo-Ins induces cellular pathways involving
Akt and show that (a) exposure of preimplantation embryos to myo-Ins increases the number of blastocysts available for uterine
transfer and of delivered animals and (b) the developmental patterns of mice obtained from embryos cultured in the presence or
absence of myo-Ins, up to three weeks of age, overlap. These data further identify myo-Ins as a possibly important supplement for
human preimplantation embryo culture in assisted reproduction technology.
1. Myo-Inositol
Myo-inositol (myo-Ins) is the major component of a family
of nine hexahydroxycyclohexane inositol (Ins) stereoisomers
broadly distributed in eukaryotic tissues and cells, where they
are involved in basic biological functions [1].
Ins is incorporated into cellmembrane phosphoinositides
or phosphatidyl-glycerides as phosphatidyl-inositol (PI),
which is phosphorylated by a set of specific phosphoinos-
itide-3-kinases (PI3K) to phosphatidyl-inositol phosphates.
Phosphatidyl-inositol trisphosphate (PIP3) can be further
metabolized by phospholipase C (PLC) to inositol trisphos-
phate (Ins−1,4,5P3, InsP3), which acts as second messenger
for various hormones such as FSH, TSH, and insulin [2, 3].
Inositol is the precursor of other membrane components
and glycosyl-phosphatidyl-inositol (GPI) protein-anchor
molecules (reviewed by [4]), signaling molecules (reviewed
by [5, 6]), chromatin-remodeling, and transcription-modu-
lating molecules [7]. It finally acts as a hyperosmotic stress
protectant [8].
2. Myo-Inositol in
Reproduction, Gametogenesis, and
Embryonic Development
Increasing evidence shows that myo-Ins has a physiological
role in mammalian gametogenesis and embryonic develop-
ment and a positive clinical impact on human medically
assisted reproduction.
Together with its isomer D-chiro-inositol (D-chiro-Ins),
myo-Ins acts as secondmessenger of insulin [9] and has been
widely studied for its involvement in metabolic syndrome
(reviewed by [10]) as well as for the treatment of polycystic
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ovary syndrome (PCOS) (reviewed by [11, 12]), one of the
most common female endocrine disorders [13] strictly asso-
ciated with insulin resistance [14]. Recent reports strongly
suggest that both Ins isomers can be positively associated
in the management of PCOS patients enrolled in assisted
reproduction procedures [15], with significant encouraging
clinical outcomes [16].
While D-chiro-Ins does not appear to have a clear role in
the ovary or in the testis, myo-Ins affects gametogenetic and
embryogenetic processes at several levels, having a protective,
positive role in reproduction and development (reviewed by
[17]).
Myo-Ins concentration in the reproductive tracts of male
mammals is higher than in blood serum being produced
by FSH-responsive Sertoli cells [18, 19]. Studies performed
on pathological sperm samples have shown that myo-Ins is
crucial in spermatogenesis by positively affecting sperm cell
motility [20] and mitochondrial membrane potential [21], an
apoptotic marker directly associated with cell viability. Since
these parameters are predictors of good embryos quality, the
use of myo-Ins in the andrology laboratory is now employed
to improve the recovery of sperm cells after swim-up in in
vitro fertilization (IVF) cycles [20].
As for female gametogenesis, myo-Ins is actively con-
centrated in mammalian follicular and tubal fluid, being
higher than in blood serum [22]. Respective values of myo-
Ins concentration in human follicular fluid and serum are 30-
to-40 𝜇M [23] and 10-to-20 𝜇M [24]. In addition, a positive
correlation exists between follicular myo-Ins content and
oocyte quality as well as pregnancy outcome [23].
At the ovarian level, Myo-Ins has different functions
in both follicle cells and oocytes. However, although it is
known that myo-Ins metabolism is severely deregulated in
follicle cells of PCOS patients [25], effects of this molecule
on somatic ovarian cells still need to be evaluated. We have
hypothesized that in theca and granulosa cells myo-Ins may
sustain steroidogenic activity during the ovarian cycle by
modulating the dynamics of cytoskeletal structures [26].
Research on this issue is ongoing in our laboratories.
Myo-Ins is transported into mammalian cells, including
growing and fully-grown oocytes and early preimplantation
embryo blastomeres, by a sodium cotransporter [27] and a
sodium independent transporter [28]. In oocytes, activity of
myo-Ins−derived InsP3 on the modulation of intracellular
Ca2+ concentration in response to the action of the hormones
LH and FSH [29, 30] is well known. It acts via cell-specific
receptors (InsP3-R1) [31] and appears to play a key role in
meiotic maturation [32].
Chiu et al. [33] cultured preovulatory oocytes from out-
bred mice in minimal essential medium supplemented with
myo-Ins and observed increased rates ofmaturation, IVF, and
development to the two-cell stage with respect to oocytes
cultured in medium alone, suggesting that higher availabil-
ity of myo-inositol increases both meiotic and activation
efficiencies of the oocyte. After transfer to foster mothers,
the implantation rate and postimplantation viability of these
embryos were also increased in the myo-Ins treated groups
[33].
Duringmammalian preimplantation development, activ-
ity of myo-Ins transporters ensures a robust uptake, which
progressively increases from the one-cell to the blastocyst
stage [34, 35], suggesting a parallel increase in cellular
requirement of the molecule. It has been shown that, in
preimplantation embryo blastomeres, myo-Ins is rapidly
incorporated into phosphoinositides [34], leading to raised
intracellular InsP3 levels. This led several groups, including
ours, to investigate whether myo-Ins could also have a
positive action during preimplantation development in both
the laboratory mouse and farming species.
Myo-Ins supplementation of culture media was found to
improve rabbit and bovine blastocyst formation and expan-
sion [35, 36]. Culture of rabbit embryos at the morula stage
in medium containing myo-Ins at the optimal concentration
of 75 𝜇M resulted in blastocysts expansion with a fourfold
increase in diameter when compared to that provided by
standard culture conditions [35]. Similar observations were
obtained on bovine zygotes matured and fertilized in vitro
[36], after culture in synthetic oviduct fluid medium [37] in
the presence or absence of 2.77mM myo-Ins. As a result,
blastocyst rate was higher among embryos developed in
the presence of myo-Ins [36]. To evaluate postimplantation
effects of this treatment, ten blastocysts grown in the presence
of myo-Ins were transferred to foster cows and developed to
term, producing five healthy animals [36].
With a clear interest in human assisted reproduction
technology (ART), positive data on myo-Ins in mammalian
preimplantation development prompted us to hypothesize
that inclusion of myo-Ins in embryo culture media would
result in increased numbers of high quality embryos pro-
duced by IVF/intracytoplasmic sperm injection (ICSI). We
tested this hypothesis in a previous work [38], using the
mouse embryo model [39, 40], by investigating the effects
of myo-Ins supplementation of sequential human embryo
culture media, starting 30 minutes after fertilization (p.f.)
and for the whole length of preimplantation development
(day 4 p.f.). In that study, we cultured embryos obtained by
ICSI from gametes of inbred C57BL/6N mice, in which ICSI
results in suboptimal rates of oocyte survival and blastocyst
development, when compared to hybrid mice [41]. After
fertilization in unmodified fertilization medium, embryos
were cultured in cleavage medium in the presence or absence
of 10mM myo-Ins (myo-Ins+ and myo-Ins−, resp.) and
monitored daily for developmental progression. At all-time
intervals monitored, (p.f.), myo-Ins+ embryos displayed a
faster cleavage rate, with a higher percentage of embryos at
the most advanced stage. In these embryos, early differen-
tiative events such as compaction and blastulation occurred
at the proper developmental stage, excluding apparent toxic
effects of myo-Ins. Although results scored on day 4 have
already been published [38], those recorded at intermediate
times have not been presented elsewhere and are reported in
Figures 1 and 2, together with embryo morphology observed
on day 4.
Embryos cultured in the presence of myo-Ins were devel-
opmentally advanced with respect to control embryos, being
mostly represented by expanded blastocysts with a higher
number of blastomeres, as shown by Hoechst 33343 nuclear
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Figure 1: Effect of myo-inositol medium supplementation on pronuclear formation and embryo development during the first two days of in
vitro culture. Completion of early developmental steps by zygotes cultured in the absence (grey bars) or the presence (solid bars) of 10mM
myo-inositol. Zygotes were scored 6 hours (a) and embryos at 24–26 hours (b) and 48–50 hours (c) p.f. Bars represent the mean ± SEM of
7 independent experiments of the fraction of embryos at each indicated stage. (a) N, myo-Ins− embryos (grey bars), 121; myo-Ins+ embryos
(solid bars), 123. ((b), (c)) N, myo-Ins− embryos (grey bars), 97; myo-Ins+ embryos (solid bars), 106. Asterisks indicate difference between
treatments calculated by 𝜒2 test with Yates correction for continuity: (b) 𝑃 < 0.05; (c) 𝑃 < 0.01.
staining [38]. We concluded that myo-Ins supplementation
represents an improvement of culture conditions reducing
the developmental gap typically observed between embryos
obtained and cultured in vitro and those developed in
vivo, further supporting its possible use for human embryo
preimplantation culture.
One of the issues left uncovered by these experiments
concerns the nature of biochemical pathways induced by
exposure to myo-Ins in preimplantation of embryo blas-
tomeres. Existing information suggests that possible path-
way(s) elicited by myo-Ins in mouse embryo blastomeres
and responsible for a reduced length of cell cycles and a
more efficient proliferation activity are initiated via rapid
incorporation into phosphoinositides [34], namely, PIP3,
enzymatically fostered by activity of PI3K. In turn, PIP3
is converted by PLC into diacylglycerol and InsP3, which,
by mobilizing Ca2+ stores, has already been recognized to
speed up several cellular processes, including proliferation
[42, 43]. PI3K is also responsible for the activation of the
PKB/Akt pathway [44], which is known to promote prolif-
eration of mouse embryo blastomeres [45]. As myo-Ins has
been shown to increase Akt phosphorylation and hence its
activity in mouse skeletal muscle cells [46], we hypothesized
that a critical step in enhancing embryo preimplantation
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Figure 2: Effect of myo-inositol medium supplementation on embryo development during the third and fourth days of in vitro culture.
Completion ofmid-to-late preimplantation development by embryos cultured in the absence (grey bars) or the presence (solid bars) of 10mM
myo-inositol. Embryos were scored 72–74 hours (a) and 96–98 hours (b) p.f. Bars represent the mean ± SEM of 7 independent experiments
of the fraction of embryos at each indicated stage. ((a), (b)) N, myo-Ins− embryos (grey bars), 97; myo-Ins+ embryos (solid bars), 106. Exp.
blast.: expanded blastocyst. Asterisks indicate difference between treatments calculated by 𝜒2 test with Yates correction for continuity: (a)
𝑃 < 0.05; (b) 𝑃 < 0.05. (c) Representative images of expanded and nonexpanded blastocysts observed at day 4 among myo-Ins− (1, 3) and
myo-Ins+ (2, 4) embryos; magnification: 40x (1, 2); 80x (3, 4). Black bars, 100 𝜇m. Panel (b) is modified from [38].
development may be represented by Akt activation induced
by myo-Ins supplementation [47]. We here provide the first
evidence, obtained by immunofluorescence analysis, that
myo-Ins supplementation of culture media increases ser-
ine phosphorylation of PKB/Akt in mouse preimplantation
embryos.
A second open issue in current research concerns the
safety of preimplantation embryo exposure to myo-Ins for
postimplantation and postnatal development.
Besides the reported observations on bovine embryos
[36], it could be argued that preimplantation embryos,
including human embryos, were once routinely cultured in
undefinedmedia supplemented with commercial BSA prepa-
rations or batches of bovine or human sera, which contain
variable amounts of myo-inositol, without reporting any
apparent negative effect.
In addition,myo-Ins appears important for normal devel-
opment (reviewed by [17]). Its concentration in foetal human
serum is severalfold higher than in adults, lowering only
around birth [48], and its administration during pregnancy
has positive effects on pathological conditions in both
humans [49, 50] and rodent species [51–54].
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All data hitherto reported suggest that preimplantation
embryo exposure to myo-Ins would have no detrimental
effects on further development. To obtain more direct infor-
mation on this issue, we transferred blastocysts produced in
vitro in the presence of myo-Ins into recipient foster mothers
and allowed their development to term. By this approach,
we obtained healthy offspring that appeared normal in the
sex ratio and, at least until weaning, somatometrically. These
experiments provide additional data on myo-Ins effects on
mammalian preimplantation embryos and strongly suggest
that it can be considered safe for embryo development to
term.
3. Materials and Methods
3.1. Animals. Animals (Charles River Italia, Calco, VA, Italy)
were housed in a temperature-controlled facility (22 ± 1∘C)
on a 12/12 h light/dark cycle, inside standard cages with
unlimited access to food and water. Forty-to-60-day-old
C57BL/6N mice were used as donors of oocytes and male
studs. Forty-to-60-day-old CD/1 mice were used as foster
mothers and vasectomized male studs. All experimental
procedures were conducted in accordance with the official
European guidelines for the care and use of laboratory
animals (86/609/EEC). Experimental protocols and related
procedures were approved by the Italian Ministry of Public
Health.
3.2. Culture Media. In order to model human preimplanta-
tion embryo culture, all procedures were performed in com-
mercial Quinn’s Advantage media and supplements (BioCare
Europe, Napoli, Italia), which do not contain myo-Ins, as
described [38].
3.3. Animal Treatment and Zygote Collection. Female mice
were hormonally induced by intraperitoneal injections of
5 IU pregnant mare serum gonadotropin (NHPP, Torrence
CA, USA) and, 46–48 h later, of 5 IU human chorionic
gonadotropin (Corulon, Intervet Italia, Aprilia, LT, Italy).
After mating with male mice ON, females carrying a vaginal
plug were sacrificed by cervical dislocation and cumulus-
oocyte complexes were collected from the oviducts, freed
from cumulus cells by treatment with 0.1% hyaluronidase
in Hepes buffered Quinn’s Protein Plus Advantage HTF-
Medium containing 5% human serum albumin, rinsed in
HTF-Medium, and incubated at 37∘C in Quinn’s Protein
Plus Cleavage Medium (C-Medium) under a humidified
atmosphere of 5% CO
2
in air.
3.4. Embryo Culture. One-cell embryos were positively
scored by the presence of two pronuclei and then divided
into two groups. One group was further cultured in 14 𝜇L/mL
myo-inositol (10mM, Andrositol LAB Lo.Li. Pharma, Italy)
in C-Medium and the other one in 14 𝜇L/mL phosphate
buffered saline in C-Medium. Embryo culture was performed
in 500𝜇L medium inside Falcon 4 well IVF plates without
medium replacement, as described [38]. Developing embryos
were scored daily for morphology and progression through
cleavage stages.
3.5. Detection of Phosphorylated PKB/Akt. Preimplantation
embryos at the morula or blastocyst stage were washed in
0.1M phosphate buffered saline, pH 7.4 (PBS), containing
0.3%bovine serumalbumin (BSA) (PBS-BSA), andwere then
fixed in 4%paraformaldehyde in PBS for 30min at room tem-
perature (RT). After three washes in PBS-BSA, embryos were
permeabilized in PBS containing 0.25% Tween-20 (Sigma; St.
Louis, MO) for 15min at RT and washed three times in PBS-
BSA. Permeabilized embryos were processed for immunos-
taining by an overnight incubation at 4∘C in the presence
of the primary antibody, rabbit monoclonal anti-phospho-
Akt (Ser473, #4080), anti-phospho-Akt (Thr308, #4056) or
anti-Akt (total, #9272) antibody (Cell Signaling Technology,
Beverly, MA, USA) (1 : 75), followed by washing in PBS-BSA
and 1 hr final incubationwith the secondary, andAlexa Flour-
488 conjugated secondary antibodies (Invitrogen), diluted
1 : 200 in PBS-BSA for 1 h at RT. After washing with PBS-
BSA, blastomere nuclei were counterstained with 1mg/mL
Hoechst 33343 for 10min at RT. Finally, embryoswerewashed
three times for 10min each in PBS-BSA and mounted in
PBS and glycerol (1 : 1 v/v) using coverslips. Fluorescent
signals were detected using a Zeiss AxioPlan fluorescence
microscope (Carl Zeiss, Oberkochen, Germany) at 400x
magnification. For semiquantitative analysis of fluorescence,
embryos at various developmental stages were immunos-
tained after pooling in the same drops. Fluorescence emission
was collected under similar excitation conditions and then
quantitatively analyzed by using the ImageJ software (ImageJ
1.47v, Wayne Rasband, National Institutes of Health, USA.
http://imagej.nih.gov/ij/).
3.6. Embryo Transfer and Development to Term. In ten repli-
cate experiments, embryos developed to the blastocyst stage
after 4 days of culture in myo-Ins+ C-Medium or myo-Ins−
C-Medium were transferred to the uteri of pseudopregnant
foster mothers mated 2.5 days earlier with vasectomized
males and carried to term [55]. On the day of delivery,
newborn animals were weighed, checked for gross abnor-
malities, and left to be nursed by their moms until weaning.
Preweaningmorphological analyses included body growth at
one week, fur appearance, and eye opening. Mice were finally
weighed and sexed at weaning (three weeks of age).
3.7. Chemicals. Where not stated otherwise, chemicals were
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
3.8. Data Analysis. Data were analyzed by using Student’s 𝑡-
test or 𝜒2 tests with Yates continuity correction. Statistical
analyses were performed using R: A language and environ-
ment for statistical computing (R development core team,
R foundation for statistical computing, ISBN 3-900051-07-0,
2008, Vienna, Austria. https://www.r-project.org/).
4. Results
4.1. Analysis of Myo-Ins−Dependent Akt Phosphorylation. We
have determined presence and phosphorylation of Akt in
late preimplantation stage embryos cultured in the presence
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Figure 3: Localization of phosphorylated Akt in preimplantation embryos at the morula and blastocyst stage, after continuous culture in
the presence or absence of myo-Ins. ((a), (b)) morula stage embryos; ((c), (d)) blastocyst stage embryos. In each panel, from left to right:
FITC, Hoechst 33343, merge. The same pattern was consistently observed in all embryos analyzed; panels show representative embryos.
Statistical analysis on these embryos, reported in the text, was performed on at least three embryos at the morula and blastocyst stages in
three independent experiments.
Table 1: Effect of myo-Ins on Akt phosphorylation of late preim-
plantation mouse embryos.
Morulae Blastocysts
Ser473 Thr308 Ser473 Thr308
Myo-Ins+ 65.41 ± 5.01 47.77 ± 4.37 49.33 ± 6.16 32.15 ± 1.56
Myo-Ins− 59.80 ± 2.55 45.87 ± 2.23 38.32 ± 2.54a 33.09 ± 2.03
Data represent arbitrary fluorescence units (mean ± SD) of embryos at the
stages indicated, pooled from three replicate experiments.
a
𝑃 = 0.02, calculated by Student’s 𝑡-test.
or absence of myo-Ins by immunofluorescence analysis.
This approach revealed the presence of serine 473- and
threonine 308-phosphorylated Akt in both morula and blas-
tocyst embryos (Figure 3). Phosphorylated Akt was localized
prominently in blastomere cytosols but a limited nuclear
localization was also observed. The relative content of phos-
phorylated Akt at the same stages was also measured by
quantification of immunofluorescence data (Table 1). The
level of serine 473-phosphorylated Akt did not appear to be
modified in embryos cultured in the presence of myo-Ins at
the morula stage (𝑡4 = 1.75, 𝑃 = 0.15) (Figure 3(a)) but it
was increased at the blastocyst stage (𝑡4 = 3.61, 𝑃 = 0.02)
(Figure 3(c)). On the contrary, the level of threonine 308-
phosphorylated Akt did not vary significantly depending on
the presence or absence of myo-Ins (morulae, 𝑡4 = 0.670,
𝑃 = 0.54, Figure 3(b); blastocysts, 𝑡4 = 0.640, 𝑃 =
0.56, Figure 3(d)). Amounts of total Akt did not vary under
different conditions (not shown).
4.2. Effects of Preimplantation Embryo Exposure to Myo-Ins
on Development to Term. In ten replicate experiments, all
embryos that had developed in vitro to the expanded or
nonexpanded blastocyst stage in the presence or absence
Table 2: Mouse development after IVF and exposure of preimplan-
tation embryos to myo-Ins.
Number of
fertilized
oocytes
Number of
transferred
blastocysts (%)
Number of
delivered
animals (%)
Myo-Ins+ 154 105 (68.2) 59 (38.3)
Myo-Ins− 147 76 (51.7)a 33 (22.5)a
Data were pooled from ten replicate experiments.
Superscripts indicate differences between myo-Ins+ and myo-Ins− embryos
(𝑃 < 0.05) calculated by 𝜒2 test; differences are referred to fertilized oocytes.
of myo-Ins were transferred to foster mothers and allowed
to develop through birth and until weaning. Of 105 myo-
Ins+ and 76 myo-Ins− blastocysts transferred, 59 (56.2%)
and 33 (43.4%), respectively, were delivered (𝜒2 = 2.876,
𝑃 = 0.09). Although this difference was not significant, when
we compared numbers of delivered animals with numbers
of fertilized oocytes cultured under the two conditions,
154 myo-Ins+ one-cell embryos and 147 myo-Ins− one-
cell embryos, we obtained a significant improvement in the
overall efficiency of the treatment (𝜒2 = 8.91, 𝑃 = 0.003).
A similar difference was observed by comparing numbers
of fertilized oocytes with numbers of transferred embryos
(𝜒2 = 8.52, 𝑃 = 0.003). Overall results are shown in Table 2.
Body weights at birth were 1.42±0.01 g for myo-Ins+ and
1.41 ± 0.02 g for myo-Ins− (𝑡90 = 0.645, 𝑃 = 0.52). During
the first week, six and four pups were found dead in the
myo-Ins+ and myo-Ins− groups, respectively. Somatometric
development appeared similar in mice of both groups, with
appropriate acquisition of body fur and eye opening.Weights
at one week of age were also similar (myo-Ins+, 2.06 ±
0.16 g, myo-Ins−, 2.08 ± 0.19 g; 𝑡80 = 0.286, 𝑃 = 0.78).
Sex distributions in the two conditions were both casual
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(myo-Ins+, 27 males, 26 females, myo-Ins−, 14 males, 15
females). Finally, weights at three weeks of age were similar
for sexes and embryo culture conditions (males: myo-Ins+,
10.20±0.21 g;myo-Ins−, 10.29±0.28 g, 𝑡39 = 0.790,𝑃 = 0.43;
females: myo-Ins+, 9.90 ± 0.19 g; myo-Ins−, 9.75 ± 0.40 g,
𝑡39 = 1.214, 𝑃 = 0.23).
5. Discussion
Akt represents a major downstream effector of growth fac-
tors, cytokines, and adhesion receptors capable of promoting
cell survival and proliferation [56, 57] and is regulated, among
others, by PIP3, the second messenger product of PI3K, via
recruitment of PDK1. PDK1 induces direct phosphorylation
at threonine 308 [58] and appears to be also implicated in
the negative regulation of phosphorylation at serine 473, by
direct binding to this hydrophobic site. However, PDK1 can
be displaced by an appropriate signal [59, 60], including
activation of integrin Like Kinase (ILK) [44], allowing Akt
autophosphorylation or phosphorylation by other kinases at
serine 473 [58]. This pathway makes Akt phosphorylation of
serine 473 inducible by upstream signals; on the contrary,
phosphorylation of threonine 308 appears to have a consti-
tutive nature [56].
We have previously shown that, during the first two
stages of embryo development, Akt phosphorylation is not
prevented by inhibition of either PI3K or PDK1 and con-
cluded that the phosphorylation state and the intracellular
distribution of Akt in two-cell embryos are independent of
the activity of both kinases. This suggested that Akt is inher-
ited from the oocyte in its phosphorylated/dephosphorylated
form at both serine 473 and threonine 308 [45].
We now show by quantitative immunofluorescence anal-
ysis that serine 473 phosphorylation of Akt can be increased
in late preimplantation embryos by the presence of myo-
Ins in the culture medium. It thus appears that, after the
initial stages of development, new phosphorylation of Akt
may occur in mid-to-late preimplantation stages depend-
ing on availability of myo-Ins. In agreement with previous
observations that development of mouse preimplantation
embryos requires PI3K activity from the 8/16-cell stage [45],
it would be reasonable to hypothesize that this finding can
be ascribed to the increased production of phosphoinositides
[34] and consequent increased production of PIP3 by PI3K.
An increase in phosphorylation of Akt may be responsible
for the faster developmental rate of embryos cultured in the
presence of myo-Ins.
The lack of inducibility of threonine phosphorylation of
Akt by myo-Ins is also in agreement with previous observa-
tions [56].
It is puzzling that myo-Ins exerts opposite effects on
both PI3K and Akt activities when added to cancer cell
cultures [61], in which it has been found to reduce PI3K
levels as well as Akt activity by inhibiting its phosphorylation.
To this respect, it is therefore tempting to speculate that
such effect could be considered context-dependent and that
some other still unknown factors are likely to participate
in modulating the PI3K/Akt pathway. In order to obtain
more specific information on this pathway, we are currently
analyzing the effects of myo-Ins both on development and
on Akt phosphorylation in preimplantation embryo in the
presence of inhibitors of PI3K and PDK1 [45]. Further
experiments will address the involvement on proliferative
activity of preimplantation embryos blastomeres of pro- and
anti-apoptotic factors of the Bcl-2 family [62].
Data here produced represent a first assessment of the
effect of preimplantation embryo exposure to myo-Ins on
mouse development to term.
So far, information on this issue in mammals is limited to
one finding obtained on bovine embryos cultured in the pres-
ence of 2.77mM myo-Ins [36]. In that study no comparison
was made between embryos cultured in the two conditions,
but blastocysts that had developed after preimplantation
exposure to myo-Ins were transferred producing healthy
animals.
Present results obtained in the mouse show (a) the appar-
ent absence of early toxic effects of myo-Ins, as suggested
by normal prenatal and short-term postnatal development,
and (b) a significant increase in the overall rate of live births
obtained after preimplantation embryo culture in myo-Ins
and subsequent transfer into foster mothers.
If the first observationwas expected in light of the body of
information here reported on the positive effects displayed by
myo-Ins onmammalian gametogenesis anddevelopment, the
second one deserves particular attention. In fact, it supports
the possibility that a regular use of myo-Ins as culture
supplement provides high efficiency in the production of
viable preimplantation embryo in vitro both in themouse and
in farming specie with promising outcome for both scientific
and economic purposes.
In addition, it strengthens the hypothesis that the use
of myo-Ins would have a similar positive role in the culture
of in vitro produced human embryos, with obvious medical
consequences.
To this end, however, additional assessments of myo-Ins
effects are necessary at least at three different levels [63]:
(a) on the expression of imprinted genes during develop-
ment; (b) on the acquisition of sensory/motor/behavioral
functions during early development; and (c) on long-term
consequences on the whole organism.
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